选择性经尿道膀胱肿瘤电切术治疗浸润性膀胱尿路上皮癌的可行性及对患者生存质量的影响被引量：6

导出

摘要目的探讨选择性经尿道膀胱肿瘤电切术(TURBT)治疗肌层浸润性膀胱尿路上皮癌(MIBUC)的可行性及对患者生存质量的影响.方法选择64例MIBUC患者随机分为TURBT组与膀胱部分切除术(PC)组,各32例.对比两组的生存质量评分及1年、3年、5年生存率.结果 TURBT组手术时间、术中出血量、术后膀胱冲洗时间、住院时间及并发症率均显著低于PC组(P<0.05);术后6个月,TURBT组QLQ-C30量表中功能评分、总体健康评分均显著高于术前及PC组,症状评分均显著低于术前及PC组(P<0.05);TURBT组中位无瘤生存期(DFS)及总生存期(OS)为34.56个月、45.11个月,与PC组为35.31个月、47.39个月比较差异无统计学意义(P>0.05);TURBT组复发率为30.00%,与PC组的27.59%比较差异无统计学意义(P>0.05);两组的1年、3年、5年DFS及OS率比较差异无统计学意义(P>0.05).结论选择性TURBT治疗的MIBUC安全可行,能够减少手术创伤、加快术后康复速度并改善生活质量.

作者赵明胡忠春张文才

机构地区齐齐哈尔医学院附属第三医院

出处《中国地方病防治》北大核心 2017年第12期1392-1393,共2页 Chinese Journal of Control of Endemic Diseases

基金齐齐哈尔市科学技术计划项目

关键词浸润性膀胱尿路上皮癌膀胱部分切除术经尿道膀胱肿瘤电切术选择标准生存质量

分类号 R737.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1冷福.探讨肌层浸润性膀胱尿路上皮癌保留膀胱手术的有效性及安全性[J].世界最新医学信息文摘,2015,0(43):55-55. 被引量：3
2马宝杰,李海波,张昌文,姚丙,杨阔,乔宝民,张志宏,徐勇.膀胱部分切除术治疗盆腔淋巴结阴性的肌层浸润性膀胱癌100例生存分析[J].中华泌尿外科杂志,2013,34(5):347-351. 被引量：28

二级参考文献20

1Knoedler JJ, Boorjian SA, Kim SP, et al. Does partial cystecto- my compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy: a matched case-control analysis. J Urol, 2012, 188: 1115-1119.
2von der Maase H, Hansen SW, Roberts .IT, et al. Gemcitabine and cisplatin versus metbotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, muhicenter, phase Ⅲ study. J Clin Oncol, 2000, 18: 3068-3077.
3Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al. Partial cystectomy: a contemporary review of the Memorial Sloan- Kettering Cancer Center experience and recommendations for pa- tient selection. J Urol, 2004, 172: 878-881.
4Kassouf W, Swanson D, Ashish M, et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder : a contempo- rary review of the M. D. Anderson Cancer Center experience. J Urol, 2006, 175: 2058-2062.
5Smaldone MC, Jacobs BL, Smaldone AM, et al. Long-term results of selective partial cystectomy for invasive urothelial bladder carci- noma. Urology, 2008, 72: 613-616.
6Koga F, Kihara K, Yoshida S, et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the ini- tial 46 patients. BJU Int, 2012, 109 : 860-866.
7Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol, 2001, 19: 666-675.
8Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cys- tectomy for bladder cancer today: a homogeneous series without neoadjuvant therapy. J Clin Oncol, 2003, 21: 690-696.
9Cho KS, Seo HK, Joung JY, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol, 2009, 182: 2625-2630.
10Bolenz C, Herrmann E, Bastian PJ, et al. Lymphovascular inva- sion is an independent predictor of oncological outcomes in pa- tients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int, 2010, 106: 493-499.